Biopolym. Cell. 2011; 27(1):53-58.
http://dx.doi.org/10.7124/bc.000082
Molecular and Cell Biotechnologies
Expression and secretion of human recombinant LIF by genetically modified mammalian cells
1Rymar S. Yu., 1Ruban T. A., 1Irodov D. M., 1Kordium V. A.
  1. Institute of Molecular Biology and Genetics, NAS of Ukraine
    150, Akademika Zabolotnoho Str., Kyiv, Ukraine, 03680

Abstract

The aim of this work was to express the human LIF gene in mammalian cells and to study the secretion of recombinant LIF into culture medium. Methods. Recombinant LIF was detected by Western blot analysis and immunoprecipitation in culture medium of CHO-K1, L-M (TK–) (ins+), 293T cells, transfected with recombinant plasmids containing human LIF gene. Results. The recombinant plasmids. containing human gene LIF, were constructed. The cells of three (CHO-K1, L-M (TK–) (ins+), 293T) mammalian lines were transfected with these plasmids. It was shown that the transfected mammalian cells secreted recombinant human LIF which was characterized by variable degree of glycosylation including completely glycosylated form (approximately 68 kD). Conclusions. The conditioned medium of developed cell lines can be used as a sour?e of human recombinant LIF for different purposes, including purification of human recombinant LIF and as an additional supplement for cell culturing.
Keywords: recombinant LIF, expression, secretion, transfection, cell lines
Full text: (PDF, in English) (PDF, in Russian)

References

[1] Auernhammer C. J., Melmed S. Leukemia inhibitory factor – neuroimmune modulator of endocrine function Endocrin. Revs 2000 21, N 3 P. 313–345.
[2] Matsuda T., Nakamura T., Nakao K. T., Katsuki M., Heike T., Yokota T. STAT3 activation is sufficient to maintain an undifferentiated state of mouse embryonic stem cells EMBO J 1999 18, N 15:4261–4269.
[3] Zandstra P. W., Le H. V., Daley G. Q., Griffith L. G., Lauffenburger D. A. Leukemia inhibitory factor (LIF) concentration modulates embryonic stem cell self-renewal and differentiation independently of proliferation Biotechnol. Bioeng 2000 69, N 6:607–617.
[4] Wright L. S., Li J., Caldwell M. A., Wallace K., Johnson J. A., Svendsen C. N. Gene expression in human neural stem cells: effects of leukemia inhibitory factor J. Neurochem 2003 86, N 1:179–195.
[5] Carpentera M. K., Cuib X., Hua Z., Jacksona J., Shermana S., Seigerc A., Wahlberga L. U. In vitro expansion of a multipotent population of human neural progenitor cells Exp. Neurol 1999 158, N 2:265–278.
[6] Pat. USA 7109032. Serum-free medium for mesenchymal stem cells / R. Cancedda, B. Dozin Publ. 09/19/2006.
[7] Pat. USA 6432711. Embryonic stem cells capable of differentiating into desired cell lines / J. H. Dinsmore, J. Ratliff Publ. 8/13/2002.
[8] Pat. USA 7534607. Method of producing cardiomyocytes from mesenchymal stem cells / W. Chen, S. Lin Publ. 19.05.2009.
[9] Dimaracis I., Levicar N., Nihoyannopoulos P. In vitro stem cell differentiation into cardiomyocytes: Part 1.Culture medium and growth factors J. Cardiothor. Renal Res 2006 1, N 2 :107–114.
[10] Gearing P. D., Gough N. M., King J. A., Hilton D. J., Nicola N. A., Simpson R. J., Nice E. C., Kelso A., Metcalf D. Molecular cloning and expression of cDNA encoding a murine myeloid leukaemia inhibitory factor (LIF) EMBO J 1987 6, N 13 : 3995–4002.
[11] Brinsden P. R., Alam V., De Moustier B., Engrand P. Recombinant human leukemia inhibitory factor does not improve implantation and pregnancy outcomes after assisted reproductive techniques in women with recurrent for unexplained implantation failure Fertil. Steril 2009 91, N 4 :1445–1447.
[12] Hossler P., Khattak S. F., Jian Z. Optimal and consistent protein glycosylation in mammalian cell culture// Glycobiology 2009 19, N 9 P. 936–949.
[13] Pat. USA 6673575. Method for preparing polypeptides with appropriate glycosilation / F. Reinhard, E. Horst, W. Claus Publ. 10.06.1999.
[14] Bork K., Horstkorte R., Weidemann W. Increasing the sialylation of therapeutic glycoproteins: The potential of the sialic acid biosynthetic pathway J. Pharmaceutic. Sci 2009 98, N 10 P. 3499–3508.
[15] Pat. USA 7118746. Conditioned cell culture medium compositions and methods of use / G. K. Naughton, D. L. Horwitz, M. A. Applegate, J. Zeltinger, J. N. Mansbridge, A. Kern, L. K. Landeen, A. Ratcliffe, R. E. Pinney Publ.10.10.2006.
[16] Pat. USA 7723105. Conditioned cell culture medium, method to obtained the same and use of it for maintenance, proliferation and differentiation of mammalian cells / V. Bordoni, T. Alonzi, M. Tripodi Publ. 5/25/2010.
[17] Makino H., Hasuda H., Ito Y. Immobilization of leukemia inhibitory factor (LIF) to culture murine embryonic stem cells J. Biosci. Bioeng 2004 98, N 5 P. 374–379.
[18] Kameda T., Sugiyama T. Application of genetically modified feeder cells for culture of keratinocytes Meth. Mol. Biol 2005 289, N 1 P. 29–38.
[19] Sidhu K. S., Lie K. H., Tuch B. E. Transgenic human fetal fibroblasts as feeder layer for human embryonic stem cell lineage selection Stem Cells Dev 2006 15, N 5 P. 741–747.
[20] Unger C., Gao S.,Cohen M., Jaconi M., Bergstrom R., Holm F., Galan A., Sanchez E., Irion P., Dubuisson J. B., Giry-Laterriere M., Salmon P., Simon C., Hovatta O., Feki A. Immortalized human skin fibroblast feeder cells support growth and maintenance of both human embryonic and induced pluripotent stem cells Hum. Reprod 2009 24, N 10 P. 2567– 2581.
[21] Jayapal K. P., Wlaschin K. F., Yap M. G. S., Hu W.-S. Recombinant protein therapeutics from CHO cells – 20 years and counting Chem. Eng. Prog 2007 103, N 7 P. 40–47.
[22] Maniatis T., Fritsch E. F., Sambrook J. Molecular cloning: a laboratory manual New York: Cold Spring Harbor Lab. publ., 1982 545 p.
[23] Geisse S., Henke M. Large-scale transient transfection of mammalian cells: a newly emerging attractive option for recombinant protein production J. Struct. Funct. Genomics 2005 6, N 2–3 P. 165–170.
[24] Laemmli U. K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4 Nature 1970 227, N 5259:680–685.
[25] Schmelzer C. H., Harris R. J., Butler D., Yedinak C. M., Wagner K. L., Burton L. E. Glycosylation pattern and disulfide assignment of recombinant human differentiation-stimulating factor Arch. Biochem. Biophys 1993 302, N 2 P. 484–489.
[26] Schmelzer C. H., Burton L. E., Tamony C. M. Purification and partial characterization of recombinant human differentiation-stimulating factor Protein Exp. Purific 1990 1, N 1 P. 54–62.
[27] Pat. USA 004098. Leukemia inhibitory factor / N. M. Gough, T. A. Willson, D. Metcalf, D. J. Hilton, E. C. Nice, N. A. Nicola, R. J. Simpson, J. A. King, D. P. Gearing Publ. 02.01.2003.
[28] Gascan H., Anegon I., Praloran V., Naulet J., Godard A., Soulillou J. P., Jacques Y. Constitutive production of human interleukin for DA cells/leukemia inhibitory factor by human tumor cell lines derived from various tissues J. Immunol 1990 144, N 7 P. 2592–2598.
[29] Godard A., Gascan H., Naulet J., Peyrat M. A., Jacques Y., Soulillou J. P., Moreau J. F. Biochemical characterization and purification of HILDA, a human lymphokine active on eosinophils and bone marrow cells Blood 1988 71, N 6 P. 1618–1623.